Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael R Jacobs

Showing results (211-220 of 231) with videos related to

Pageof 24
Sort By:
The Journal of Antimicrobial Chemotherapy|January 22, 2009
Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USAAndrea Endimiani, Andrea M Hujer, Federico Perez, et al.
Antimicrobial Agents and Chemotherapy|July 30, 2014
Extensively drug-resistant pseudomonas aeruginosa isolates containing blaVIM-2 and elements of Salmonella genomic island 2: a new genetic resistance determinant in Northeast OhioFederico Perez, Andrea M Hujer, Steven H Marshall, et al.
European Journal of Medicinal Chemistry|May 2, 2021
A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter sppJoel A Goldberg, Vijay Kumar, Elizabeth J Spencer, et al.
Antimicrobial Agents and Chemotherapy|October 30, 2024
ARGONAUT-IV: susceptibility of carbapenemase-producing <i>Klebsiella pneumoniae</i> to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibutenMichael R Jacobs, Caryn E Good, Ayman M Abdelhamed, et al.
Antimicrobial Agents and Chemotherapy|August 12, 2024
ARGONAUT-III and -V: susceptibility of carbapenem-resistant <i>Klebsiella pneumoniae</i> and multidrug-resistant <i>Pseudomonas aeruginosa</i> to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepimeMichael R Jacobs, Ayman M Abdelhamed, Caryn E Good, et al.
Mbio|March 14, 2019
Targeting Multidrug-Resistant <i>Acinetobacter</i> spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic AgentMelissa D Barnes, Vijay Kumar, Christopher R Bethel, et al.
Antimicrobial Agents and Chemotherapy|September 27, 2006
Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical CenterKristine M Hujer, Andrea M Hujer, Edward A Hulten, et al.
Journal of Medicinal Chemistry|April 10, 2018
Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234Krisztina M Papp-Wallace, Nhu Q Nguyen, Michael R Jacobs, et al.
Antimicrobial Agents and Chemotherapy|April 18, 2022
Imipenem/Relebactam Resistance in Clinical Isolates of Extensively Drug Resistant Pseudomonas aeruginosa: Inhibitor-Resistant β-Lactamases and Their Increasing ImportanceAndrea M Hujer, Christopher R Bethel, Magdalena A Taracila, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 22, 2018
Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IVScott R Evans, Thuy Tien T Tran, Andrea M Hujer, et al.
Pageof 24

Showing results (211-220 of 231) with videos related to

Sort By:
Pageof 24
The Journal of Antimicrobial Chemotherapy|January 22, 2009
Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USAAndrea Endimiani, Andrea M Hujer, Federico Perez, et al.
Antimicrobial Agents and Chemotherapy|July 30, 2014
Extensively drug-resistant pseudomonas aeruginosa isolates containing blaVIM-2 and elements of Salmonella genomic island 2: a new genetic resistance determinant in Northeast OhioFederico Perez, Andrea M Hujer, Steven H Marshall, et al.
European Journal of Medicinal Chemistry|May 2, 2021
A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter sppJoel A Goldberg, Vijay Kumar, Elizabeth J Spencer, et al.
Antimicrobial Agents and Chemotherapy|October 30, 2024
ARGONAUT-IV: susceptibility of carbapenemase-producing <i>Klebsiella pneumoniae</i> to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibutenMichael R Jacobs, Caryn E Good, Ayman M Abdelhamed, et al.
Antimicrobial Agents and Chemotherapy|August 12, 2024
ARGONAUT-III and -V: susceptibility of carbapenem-resistant <i>Klebsiella pneumoniae</i> and multidrug-resistant <i>Pseudomonas aeruginosa</i> to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepimeMichael R Jacobs, Ayman M Abdelhamed, Caryn E Good, et al.
Mbio|March 14, 2019
Targeting Multidrug-Resistant <i>Acinetobacter</i> spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic AgentMelissa D Barnes, Vijay Kumar, Christopher R Bethel, et al.
Antimicrobial Agents and Chemotherapy|September 27, 2006
Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical CenterKristine M Hujer, Andrea M Hujer, Edward A Hulten, et al.
Journal of Medicinal Chemistry|April 10, 2018
Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234Krisztina M Papp-Wallace, Nhu Q Nguyen, Michael R Jacobs, et al.
Antimicrobial Agents and Chemotherapy|April 18, 2022
Imipenem/Relebactam Resistance in Clinical Isolates of Extensively Drug Resistant Pseudomonas aeruginosa: Inhibitor-Resistant β-Lactamases and Their Increasing ImportanceAndrea M Hujer, Christopher R Bethel, Magdalena A Taracila, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 22, 2018
Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IVScott R Evans, Thuy Tien T Tran, Andrea M Hujer, et al.
Pageof 24